Zydus Lifesciences receives USFDA approval for Empagliflozin and Metformin Hydrochloride Tablets

11 Jul 2022 , 11:04 AM

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Empagliflozin and Metformin Hydrochloride Tablets in the strengths of 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, and 12.5 mg/1000 mg (US RLD: Synjardy?). Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease. The drug will be manufactured at the groups formulation facility at SEZ, Ahmedabad, India.Powered by Capital Market – Live News